Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma

(2021) David Siegel et al.   LEUKEMIA & LYMPHOMA

P-191: Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma

(2021) Ajai Chari et al.   Clinical Lymphoma Myeloma & Leukemia

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

(2020) Evangelos Terpos et al.   LEUKEMIA

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

(2020) Maria-Victoria Mateos et al.   Lancet Haematology

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

(2020) Meletios Dimopoulos et al.   LANCET

Mechanisms of lenalidomide sensitivity and resistance

(2020) Sergio Martinez-Høyer et al.   EXPERIMENTAL HEMATOLOGY

Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations

(2019) Corrado Girmenia et al.   BLOOD REVIEWS

Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

(2019) Ajai Chari et al.   BLOOD

Carfilzomib for relapsed and refractory multiple myeloma

(2019) K. Groen et al.   Cancer Management and Research

Relapsed refractory multiple myeloma: a comprehensive overview

(2019) Abdul Hamid Bazarbachi et al.   LEUKEMIA

Drug resistance in multiple myeloma

(2018) Pawel Robak et al.   CANCER TREATMENT REVIEWS